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Abstract
Background: Microglia reactivity is a hallmark of retinal degenerations and overwhelming microglial responses
contribute to photoreceptor death. Minocycline, a semi-synthetic tetracycline analog, has potent anti-inflammatory
and neuroprotective effects. Here, we investigated how minocycline affects microglia in vitro and studied its
immuno-modulatory properties in a mouse model of acute retinal degeneration using bright white light exposure.
Methods: LPS-treated BV-2 microglia were stimulated with 50 μg/ml minocycline for 6 or 24 h, respectively.
Pro-inflammatory gene transcription was determined by real-time RT-PCR and nitric oxide (NO) secretion was
assessed using the Griess reagent. Caspase 3/7 levels were determined in 661W photoreceptors cultured with
microglia-conditioned medium in the absence or presence of minocycline supplementation. BALB/cJ mice received
daily intraperitoneal injections of 45 mg/kg minocycline, starting 1 day before exposure to 15.000 lux white light for
1 hour. The effect of minocycline treatment on microglial reactivity was analyzed by immunohistochemical stainings of
retinal sections and flat-mounts, and messenger RNA (mRNA) expression of microglia markers was determined using
real-time RT-PCR and RNA-sequencing. Optical coherence tomography (OCT) and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) stainings were used to measure the extent of retinal degeneration
and photoreceptor apoptosis.
Results: Stimulation of LPS-activated BV-2 microglia with minocycline significantly diminished the transcription
of the pro-inflammatory markers CCL2, IL6, and inducible nitric oxide synthase (iNOS). Minocycline also reduced the
production of NO and dampened microglial neurotoxicity on 661W photoreceptors. Furthermore, minocycline had
direct protective effects on 661W photoreceptors by decreasing caspase 3/7 activity. In mice challenged with white
light, injections of minocycline strongly decreased the number of amoeboid alerted microglia in the outer retina and
down-regulated the expression of the microglial activation marker translocator protein (18 kDa) (TSPO), CD68, and
activated microglia/macrophage whey acidic protein (AMWAP) already 1 day after light exposure. Furthermore, RNA-seq
analyses revealed the potential of minocycline to globally counter-regulate pro-inflammatory gene transcription in the
light-damaged retina. The severe thinning of the outer retina and the strong induction of photoreceptor apoptosis
induced by light challenge were nearly completely prevented by minocycline treatment as indicated by a preserved
retinal structure and a low number of apoptotic cells.
Conclusions: Minocycline potently counter-regulates microgliosis and light-induced retinal damage, indicating
a promising concept for the treatment of retinal pathologies.
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Background
Age-related macular degeneration (AMD) is a leading
cause of severe visual impairment in the elderly, and the
number of affected persons steadily increases as a conse-
quence of demographic changes [1]. Late stage AMD can
be classified in a dry and a wet form, representing atrophic
and neovascular processes, respectively. Wet AMD can be
treated with intravitreal injections of anti-vascular endo-
thelial growth factor (VEGF) medication, while no estab-
lished treatment options exist for the dry form [2]. The
pathogenesis of AMD is characterized by the early pres-
ence of drusen, damage of the retinal pigment epithelium
(RPE) and photoreceptor layer primarily affecting the
macular region and a chronic inflammatory response in
the retina leading to the expression of pro-inflammatory
and pro-angiogenic factors [2]. This immunological re-
sponse in the retina can be regarded as para-inflammation
and involves the reactivity of microglial cells [3–5].
Microglial cells are the tissue macrophages of the cen-
tral nervous system (CNS), including the retina. In the
healthy adult retina, they are located in the plexiform
layers from where they permanently scan the retinal en-
vironment with their motile protrusions [6]. The expres-
sion of several receptors that are specific for the binding
of chemokines, cytokines, complement factors, anti-
bodies, or damage-associated molecular patterns enables
these cells to recognize and immediately respond to
pathological changes of their environment [7–9]. Besides
their supportive function in the healthy retina, microglia
reactivity and age-related changes of microglia physi-
ology contribute to degenerative pathologies of the ret-
ina and the entire CNS [3, 4, 8, 10–17]. A large number
of amoeboid shaped reactive microglia are detectable in
the degenerating photoreceptor layer of AMD and retin-
itis pigmentosa retinas [4]. These cells contain phagocy-
tosed rhodopsin-positive particles [4], and a recent
report demonstrated that microglia do not only phago-
cytose dead cells but also take up living rods in a mouse
model for retinitis pigmentosa [13]. Therefore, microglial
activation cannot be just regarded as a bystander effect
but rather actively contributes to photoreceptor cell
death during retinal degeneration.
Because of these findings, substances that modulate
microglial reactivity such as minocycline are good candi-
dates to prevent inflammation and dampen degenerative
processes in the retina. Minocycline is a second-generation
semi-synthetic tetracycline analog, which is used against
Gram-positive and Gram-negative bacteria for over 30 years.
Besides its bacteriostatic capacity, minocycline exerts anti-
inflammatory, anti-apoptotic, and neuroprotective effects in
experimental models of Parkinson’s disease [18], multiple
sclerosis [19–22], neuropathic pain [16], Alzheimer’s
disease [23, 24], and in a genetic mouse model of retinitis
pigmentosa [25].
In this study, we addressed the questions how minocy-
cline modulates microglial reactivity in vitro and whether
it protects from acute white light-induced retinal degener-
ation in the mouse. We selected white light exposure as it
is an environmental risk factor that mimics several fea-
tures of AMD in rodents including degeneration of photo-
receptors and the retinal pigment epithelium [26–28].
This model is also very useful for a temporal correlation
of microglial responses with processes of retinal degener-
ation and RPE dysfunction [29–31].
Methods
Reagents
Minocycline hydrochloride (M9511), Escherichia coli
0111:B4 lipopolysaccharide (LPS), and Z-Leu-Leu-Leu-al
(MG-132) were purchased from Sigma-Aldrich (St. Louis,
MO, USA).
Cell culture
BV-2 microglia were cultured in RPMI1640 with 5 %
fetal calf serum (FCS) supplemented with 2 mM L-
glutamine, 1 % penicillin/streptomycin, and 195 nM
β-mercaptoethanol at 37 °C in a humidified atmosphere
of 5 % CO2, as described previously [32, 33]. BV-2 cells
were pre-incubated for 30 min with 50 μg/ml minocycline
or NaCl as vehicle control. Afterwards, the cells were
stimulated with 50 ng/ml LPS, 50 μg/ml minocycline, or
50 ng/ml LPS plus 50 μg/ml minocycline for 24 h. After
stimulation, cells or supernatant were harvested for fur-
ther analysis. 661W photoreceptor-like cells were a kind
gift from Prof. Muayyad Al-Ubaidi (Department of Cell
Biology, University of Oklahoma Health Sciences Center,
Oklahoma City, OK, USA). 661W photoreceptor cells
were cultured with Dulbecco’s modified Eagle’s medium
(DMEM), high glucose with L-glutamine, supplemented
with 10 % FCS and 1 % penicillin/streptomycin. Cultures
were maintained in a sterile humidified environment at
37 °C and 5 % CO2 as described elsewhere [34].
RNA isolation and reverse transcription
Total RNA was extracted from cultured BV-2 micro-
glia or murine retinas using the NucleoSpin® RNA
Mini Kit (Macherey-Nagel, Dueren, Germany). RNA
was quantified spectrophotometrically with a NanoDrop
2000 (Thermo Scientific). First-strand complemen-
tary DNA (cDNA) synthesis was carried out with the
Revert Aid H Minus First-strand cDNA Synthesis Kit
(Fermentas, K1632).
Real-time RT-PCR
cDNA (25 ng) were amplified in a 10-μl reaction mixture
consisting of 5 μl Fast Start Universal Probe Master (Rox)
(Roche), 2 μl of primers (10 μM), 0.375 μl purified water,
and 0.125 μl of dual-labeled Universal ProbeLibrary (UPL)
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probe (Roche Applied Science, Basel, Switzerland) with an
Applied Biosystems 7900 HT Fast Real-time PCR system
(Applied Biosystems, Carlsbad, CA, USA). The following
reaction parameters were used: 10 min 95 °C hold,
followed by 40 cycles of 15 s 95 °C melt, and 1 min
60 °C anneal/extension. Primer sequences and UPL
probe numbers were as follows: CD68, forward primer 5′-
ctctctaaggctacaggctgct-3′, reverse primer 5′-tcacggttgcaag
agaaaca-3′, probe #27; activated microglia/macrophage
whey acidic protein (AMWAP), forward primer 5′-tttgatc
actgtggggatga-3′, reverse primer 5′-acactttctggtgaaggcttg-
3′, probe #1; translocator protein (TSPO), forward primer
5′-actgtattcagccatggggta-3′, reverse primer 5′-accatagcgt
cctctgtgaaa-3′, probe #33; IL6, forward primer 5′-gatgg
atgctaccaaactggat-3′, reverse primer 5′-ccaggtagctatggta
ctccaga-3′, probe #6; inducible nitric oxide synthase
(iNOS), forward primer 5′-ctttgccacggacgagac-3′, reverse
primer 5′-tcattgtactctgagggctga-3′, probe #13; CCL2, for-
ward primer 5′-catccacgtgttggctca-3′, reverse primer 5′-
gatcatcttgctggtgaatgagt-3′, probe #62; CASP8, forward
primer 5′-tgaacaatgagatccccaaat-3′, reverse primer 5′-
caaaaatttcaagcaggctca-3′, probe #11; and ATP5B, forward
primer 5′-ggcacaatgcaggaaagg-3′, reverse primer 5′-tcagc
aggcacatagatagcc-3′, probe #77. Measurements were
performed in triplicates. ATP5B expression was used
as reference gene and results were analyzed with the
ABI sequence detector software version 2.4 using the
ΔΔCt method for relative quantification.
RNA-sequencing and bioinformatic data analysis
Library preparation and RNA-seq were carried out as
described in the Illumina TruSeq Stranded mRNA Sam-
ple Preparation Guide, the Illumina HiSeq 1000 System
User Guide (Illumina, Inc., San Diego, CA, USA), and
the KAPA Library Quantification Kit—Illumina/ABI
Prism User Guide (Kapa Biosystems, Inc., Woburn, MA,
USA). In brief, 300 ng of total RNA was used for purify-
ing the poly-A containing messenger RNA (mRNA)
molecules using poly-T oligo-attached magnetic beads.
Following purification, the mRNA was fragmented to an
average insert size of 200–400 bases using divalent cat-
ions under elevated temperature (94 °C for 4 min). The
cleaved RNA fragments were copied into first-strand
cDNA using reverse transcriptase and random primers.
Strand specificity was achieved by replacing dTTP with
dUTP in the Second Strand Marking Mix (SMM),
followed by second-strand cDNA synthesis using DNA
Polymerase I and RNase H. The incorporation of dUTP
in second-strand synthesis quenches the second strand
during amplification, because the polymerase used in the
assay is not incorporated past this nucleotide. The
addition of Actinomycin D to First Stand Synthesis Act
D mix (FSA) prevents spurious DNA-dependent synthe-
sis, while allowing RNA-dependent synthesis, improving
strand specificity. These cDNA fragments then had the
addition of a single “A” base and subsequent ligation of
the adapter. The products were purified and enriched
with PCR to create the final cDNA library. The libraries
were quantified using the KAPA SYBR FAST ABI Prism
Library Quantification Kit. Equimolar amounts of each
library were used for cluster generation on the cBot
(TruSeq SR Cluster Kit v3). The sequencing run was
performed on a HiSeq 1000 instrument using the
indexed, 50 cycles single read (SR) protocol and the
TruSeq SBS v3 Kit. Image analysis and base calling
resulted in .bcl files, which were converted into .fastq
files by the CASAVA1.8.2 software. Library preparation
and RNA-seq were performed at the service facility
“KFB—Center of Excellence for Fluorescent Bioanaly-
tics” (Regensburg, Germany).
The RNA express workflow on Illumina BaseSpace
was used to determine differential gene expression in
two biological replicates of control retinas, light-exposed
retinas, and light-exposed retinas treated with minocy-
cline, respectively. In brief, alignment of RNA-seq reads
to the mouse UCSC mm10 genome and mapping to
genes was performed with STAR aligner [35]. Differen-
tial gene expression between the two biological repli-
cates each was calculated with DESeq2 [36]. The cutoff
of genes considered to be differentially expressed was a
log2 fold change of ≥2 or ≤−2.
Integrative analysis of genome-wide expression activ-
ities was performed with the Gene Expression Dynamics
Inspector (GEDI), a Matlab (Mathworks, Natick, MA)
freeware program which uses self-organizing maps
(SOMs) to translate high-dimensional data into a 2D
mosaic [37]. Each tile of the mosaic represents an indi-
vidual SOM cluster and is color-coded to represent high
or low expression of the cluster’s genes, thus identifying
the underlying pattern.
The RNA-seq raw data and normalized DESeq2
counts of this study are publicly available at the National
Center for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) as series
record GSE71025.
Nitrite measurement
Nitric oxide concentrations were determined by meas-
urement of nitrite released into BV-2 culture super-
natants using the Griess reagent system (Promega).
Fifty-microliter cell culture supernatants from differ-
entially stimulated BV-2 cells were incubated with
100 μl Griess reagent in each well of a translucent
96-well plate. After incubation for 30 min at room
temperature, absorbance was measured at 540 nm
on an Infinite F200 Pro plate reader (Tecan). Nitrite
concentrations were calculated on the basis of a so-
dium nitrite reference curve.
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661 W photoreceptor apoptosis assay
To investigate microglial neurotoxicity and to assess
whether minocycline also has direct effect on photore-
ceptors, 661W cells were incubated for 48 h with culture
supernatants from differentially stimulated BV-2 cells or
culture supernatants supplemented with minocycline.
Apoptotic cell death was determined using the Caspase-
Glo® 3/7 Assay (Promega). Cells were lysed and incu-
bated with a luminogenic caspase-3/7 substrate, which
contains the tetrapeptide sequence DEVD. After incuba-
tion at room temperature for 1 h, the generated lumi-
nescence was measured on an Infinite F200 Pro plate
reader (Tecan). A blank reaction without cells was used
to determine background luminescence associated with
the cell culture system and Caspase-Glo® 3/7 reagent.
The values of the blank reactions were subtracted from
all experimental values. Negative control reactions were
performed to determine the basal caspase activity of
661 W cells. Relative luciferase units (RLU) reflect the
level of apoptotic cell death.
Animals
All experiments were performed with 10–14-weeks-old
albino BALB/cJ mice of both sexes. Animals were
housed in an air-conditioned environment with 12-h
light-dark schedule and had free access to water and
food. All experimental procedures complied with the
German law on animal protection and the ARVO
Statement for the Use of Animals in Ophthalmic and
Vision Research. The animal protocols used in this
study were reviewed and approved by the governmental
body responsible for animal welfare in the state of
Nordrhein-Westfalen (Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen, Germany) (refer-
ence number 84-02.04.2015-A039).
Minocycline administration
The mice received intraperitoneal injections of minocy-
cline at a dose of 45 mg/kg or NaCl as solvent control
where indicated twice daily for the first two days, start-
ing one day before the light exposure and once daily for
the remaining days.
Light exposure regimen
BALB/cJ mice were dark-adapted for 16 h before light
exposure. After pupil dilatation with 1 % Phenylephrin
and 2.5 % Tropicamid under dim red light, the mice
were exposed to bright white light with an intensity
of 15.000 lx for 1 h. After light exposure, the animals
were housed in dark-reared conditions overnight and
then maintained under normal light conditions for
the remaining experimental period.
Immunohistochemistry
Eyes were harvested for immunohistochemical analysis
4 days after light exposure. After fixation with 4 % para-
formaldehyde, eyes were embedded in optimal cutting
temperature (OCT) compound or dissected for retinal
flat mount analysis. Sixteen-micrometer sections were
rehydrated with PBS and blocked with dried milk solu-
tion. Flat mounts were incubated with 5 % Tween, 5 %
Triton-X100 in PBS overnight and non-specific binding
was blocked by incubation with dried milk solution.
Subsequently, retinal sections and flat mounts were
incubated with primary antibodies at 4 °C overnight.
Primary antibodies targeting the following molecules
were used: rabbit anti-Iba1 antibody (Wako Chemicals,
Neuss, Germany), rabbit anti-TSPO antibody (Abcam,
Cambridge, UK), and rabbit anti-Glial Fibrillary Acidic
Protein (G9269, Sigma). After a washing step, the sections
and flat mounts were incubated with a secondary antibody
either conjugated to Alexa488 (green) or Alexa594
(red) (Jackson Immuno-Research, West Grove, PA, USA)
for 1 h. After counterstaining with 4',6-diamidino-2-
phenylindole (DAPI), the samples were mounted in
DAKO fluorescent mounting medium (Dako Deutschland
GmbH, Hamburg, Germany) and analyzed with an Axios-
kop2 MOT Plus Apotome microscope (Carl Zeiss).
Optical coherence tomography (OCT)
Animals were anesthetized by intraperitoneal injection
of Rompun (10 mg/kg body weight)-Ketavet (100 mg/kg
body weight), and their pupils were dilated with Phenyl-
ephrine HCl (0.25 %)-Tropicamide (0.05 %) before image
acquisition. Spectral-domain OCT (SD-OCT) was per-
formed on both eyes with a Spectralis™ HRA +OCT de-
vice (Heidelberg Engineering) to investigate structural
changes in the retina after light exposure and minocy-
cline administration. Thickness measurements were per-
formed with a circular ring scan (circle diameter 1, 3, 6
ETDRS), centered on the optic nerve head, which repre-
sents the average retinal thickness [μm] in a certain field.
Central retinal thickness was calculated from four fields
around the optic nerve head using the Heidelberg Eye
Explorer Software.
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
Retinal sections were labeled with an in situ cell death
detection kit, Fluorescein (Roche) to detect the amount
of apoptotic cells 4 days after light exposure. For a better
overview, the sections were also counterstained with
DAPI for 10 min. After a washing procedure, sections
were mounted in DAKO fluorescent mounting medium
(Dako Deutschland GmbH, Hamburg, Germany) and
analyzed with an Axioskop2 MOT Plus Apotome micro-
scope (Carl Zeiss).
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Statistical analysis
Nitrite secretion, caspase 3/7 activities, and real-time
RT-PCR data from BV-2 cells were analyzed with one-way
ANOVA and Bonferroni’s multiple comparison tests.
Real-time RT-PCR data of murine retinas and OCT
measurements of retinal thickness were analyzed using a
one-way ANOVA and Dunnett’s multiple comparison
tests. p < 0.05 was considered statistically significant.
Results
Minocycline dampens the pro-inflammatory response
and neurotoxic potential of microglia and promotes
photoreceptor survival in vitro
We first investigated whether minocycline treatment
affects reactivity and neurotoxicity of BV-2 microglial
cells. Gene expression of the chemoattractant protein
CCL2, the pro-inflammatory cytokine IL6, and iNOS,
which catalyzes the generation of toxic nitric oxide
(NO), were analyzed in LPS-activated BV-2 cells that
were treated with minocycline for 6 and 24 h, respect-
ively. Minocycline significantly dampened LPS-induced
gene expression of CCL2 (Fig. 1a, p < 0.0001 for LPS ver-
sus minocycline + LPS treatment), IL6 (Fig. 1b, p = 0.002
for LPS versus minocycline + LPS treatment), and iNOS
(Fig. 1c, p < 0.0001 for LPS versus minocycline + LPS
treatment) in a short-term setting of 6-h incubation.
Minocycline also decreased mRNA expression of these
three genes after a 24-h treatment period (Fig. 1d–f ),
but the level of significance was only reached for iNOS
(Fig. 1f, p < 0.0001 for LPS versus minocycline + LPS
treatment). These findings indicate that minocycline
action on microglia is a relatively rapid process and very
likely interferes with immediate/early mechanisms of
pro-inflammatory activation.
Since iNOS levels were also significantly inhibited by
minocycline in the longer incubation experiment, we de-
termined the amount of nitric oxide produced by BV-2
cells after stimulation with LPS, minocycline, and both
compounds together after 24 h. LPS-treated microglial
cells stimulated with minocycline released significantly
less nitric oxide compared to cells that were stimulated
with LPS alone (Fig. 2a, p < 0.0001), indicating that
minocycline may reduce microglial neurotoxicity.
Using an apoptosis assay of 661W photoreceptor-like
cells treated with microglia-conditioned medium with or
without additional minocycline supplementation, we tested
whether minocycline can reduce microglial neurotoxicity
and possibly exert direct beneficial effects on photoreceptor
survival. The supernatant from LPS-stimulated microglia
significantly increased caspase 3/7 activity in 661 W cells as
a biomarker of cell death (Fig. 2b, p < 0.0001 for LPS versus
control treatment). In contrast, conditioned medium from
LPS-treated BV-2 cells that were co-stimulated with mino-
cycline induced significantly lower caspase 3/7 levels in
661 W cells (Fig. 2b, left part, p < 0.0001 for LPS versus
minocycline + LPS supernatant treatment). Furthermore,
treatment of 661W photoreceptors with supernatant from
LPS-treated BV-2 cells that was supplemented with
Fig. 1 Minocycline dampens pro-inflammatory gene transcription in microglia. BV-2 microglial cells were pre-treated with 50 μg/ml minocycline
or NaCl as a vehicle control for 30 min. The cells were then further stimulated with either 50 μg/ml minocycline, 50 ng/ml LPS, or a combination
of both. Six hours (a–c) and 24 h (d–f) later transcript levels of the pro-inflammatory marker genes CCL2 (a, d), IL6 (b, e), and iNOS (c, f) were
determined by quantitative real-time PCR. Data show mean ± SEM out of three independent experiments (n = 5/group, measured in triplicates)
with *p < 0.05, **p < 0.01, ***p < 0.001
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minocycline also reduced caspase 3/7 levels (Fig. 2b, right
part, p < 0.001 for LPS versus LPS supernatant +minocy-
cline supplement). Thus, minocycline reduced the levels of
secreted neurotoxic and pro-apoptotic molecules from
microglia but also exerted direct survival-promoting effects
on photoreceptors that were challenged with reactive
microglia-supernatants.
Minocycline prevents microglia reactivity in retinas
exposed to acute white light
To test the effects of minocycline on microglial re-
sponses in the damaged retina in vivo, we selected the
murine model of acute light-induced degeneration. This
model mimics several features of AMD including im-
mune activation and apoptosis of photoreceptor cells.
After 16 h of dark adaptation, BALB/cJ mice were ex-
posed to white light with an intensity of 15.000 lux for
1 h. The mice received daily intraperitoneal injections of
45 mg/kg minocycline, starting 1 day before the light
exposure for five consecutive days. The first 2 days, the
mice received two injections per day and then once daily
for the remaining 3 days (Fig. 3, top, schematic drawing).
Four days after light exposure, the effect of minocycline
administration was analyzed by staining of retinal sec-
tions and flat mounts with markers for reactive gliosis.
In control animals, retinal immunolabeling with the
marker Iba1 showed ramified microglia in the plexiform
layers as expected (Fig. 3a). Light exposure caused a
severe thinning of the outer nuclear layer and many
amoeboid shaped microglia appeared in the degenerating
photoreceptor layer and the subretinal area (Fig. 3b).
This prominent degeneration of photoreceptors and
accumulation of microglia in the outer retina was not
detectable in retinas of mice treated with minocycline
(Fig. 3c). To better analyze the microglial network and
localization, retinal flat mounts were stained with Iba1.
In contrast to healthy controls, where microglial cells
are absent in the outer retina, retinal flat mounts from
light-exposed mice showed high numbers of amoeboid
shaped microglia in the subretinal area (Fig. 3d, e).
Treatment with minocycline clearly prevented migration
of many microglia to the subretinal area, and the cells in
this region had a more ramified morphology (Fig. 3f ).
To better characterize the reactive phenotype of glia
cells, the expression of the activation markers TSPO for
microglia and glial fibrillary acid protein (GFAP) for
Müller cells and astrocytes were analyzed. Exposure to
light initiated a strong increase in TSPO expression, es-
pecially confined to outer retinal microglia (Fig. 3h). In
contrast, administration of minocycline strongly re-
duced TSPO expression, indicating a less reactive
microglia phenotype (Fig. 3i). Expression of GFAP in
Müller cells and astrocytes of retinas exposed to light
was also increased compared to controls (Fig. 3j, k),
whereas minocycline-treated animals displayed only weak
GFAP staining (Fig. 3l). These findings indicate that the
reactive gliosis elicited by acute light damage can be
significantly suppressed by minocycline treatment.
Minocycline counter-regulates pro-inflammatory gene
expression in retinal degeneration
In addition to these in situ analyses of retinas, we investi-
gated whether mRNA levels of microglia-related pro-
inflammatory marker genes were influenced by minocycline
Fig. 2 Minocycline stimulation dampens microglial NO production and reduces their neurotoxic potential on 661W photoreceptors. BV-2 cells
were pre-treated with 50 μg/ml minocycline or NaCl for 30 min. The cells were then further stimulated with either 50 μg/ml minocycline, 50 ng/ml
LPS, or a combination of both. a Twenty-four hours later, the nitric oxide production was determined by Griess reaction which detects the amount of
nitrite in the cell culture supernatant. Data show mean ± SEM (n = 3/group, measured in triplicates). b To determine the neurotoxic potential
of microglia, the cell culture supernatant of the differentially treated microglial cells was transferred to 661W photoreceptor cells. Furthermore,
cell culture supernatant of untreated and LPS-stimulated BV-2 cells supplemented with minocycline was transferred to 661W photoreceptor
cells to test whether minocycline may have a direct neuroprotective effect. After 48 h of incubation with microglia conditioned-medium,
apoptotic cell death was analyzed by caspase 3/7 activity measurements. Data show mean ± SEM (n = 3/group, measured in duplicates) with
*p < 0.05, **p < 0.01, ***p < 0.001
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administration in vivo. CD68, AMWAP, and TSPO are
markers that are associated with microglia proliferation and
reactivity [38–41]. Four days after light exposure all three
markers were clearly up-regulated in the retina, with
especially high induction levels of CD68 and AMWAP
(Fig. 4a–c). In mice treated with minocycline, the expres-
sion of CD68 (Fig. 4a, p = 0.0002) and AMWAP (Fig. 4b,
p = 0.007) were significantly suppressed and mRNA levels
of TSPO were reduced (Fig. 4c, p = 0.057). Furthermore,
transcripts that reflect the activation of key microglial
pathways including chemotaxis, pro-inflammatory cyto-
kines, and radical production were analyzed. In retinas of
light exposed mice that were treated with minocycline,
mRNA levels of the chemotactic molecule CCL2 were
Fig. 3 Treatment of light-exposed mice with minocycline blocks microglia reactivity and Müller cell gliosis. Of both sexes, 10- to 14-week-old
BALB/c mice were dark-adapted for 16 h. After pupil dilatation, the mice were exposed to bright white light with an intensity of 15.000 lux for
1 hour. The mice received intraperitoneal injections of minocycline at a dose of 45 mg/kg body weight twice daily for the first 2 days, starting
1 day before the light exposure and once daily for the remaining 3 days. Four days after the light exposure OCT, immunohistochemical stainings,
real-time RT-PCR analysis, and RNA sequencing were performed to determine the in vivo effects of minocycline treatment (schematic drawing).
Representative photomicrographs show retinal sections (a–c) and flat mounts (d–f) stained with Iba1 (green), TSPO (red) (g–i), and GFAP (red) (j–l).
In control retinas, microglial cells were located in the OPL, IPL, and GCL (a, d); low levels of TSPO were only observable in the GCL (g); and signs
for Müller cell gliosis were not detectable (j). b, e, h, and k Photomicrographs of light-exposed mice showed a massive thinning of the ONL
and an increased number of amoeboid shaped, reactive microglia in the ONL, and the subretinal space (b, e). h A strong up-regulation of TSPO
expression was detectable in microglia. k Up-regulation of GFAP indicates Müller cell gliosis. c, f, i, and l Representative photomicrographs of
minocycline-treated mice 4 days after light exposure. Compared to untreated controls, the ONL of minocycline-treated mice appeared markedly
preserved and less microglia were detectable in the ONL and the subretinal space (c, f). i Microglial cells were negative for TSPO expression.
l GFAP expression was only detectable in astrocytes, indicating a lack of reactive Müller cells. TSPO translocator protein, GFAP glial fibrillary acid
protein, ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer. Scale bar 50 μm
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significantly decreased compared to untreated animals
(Fig. 4d, p < 0.0001). The expression of IL6 was also ele-
vated after exposure to light and returned to baseline in
the minocycline administration group (Fig. 4e). In contrast
to our in vitro data, no significant differences in iNOS
expression were detectable after light exposure or minocy-
cline treatment after the 4-day period (Fig. 4f). This
suggests that minocycline also exerts microglia-related
anti-inflammatory effects in vivo in the retina.
Minocycline dampens early microglia responses to acute
white light
Analysis 4 days after light exposure revealed that mino-
cycline reduced the number of activated microglial cells
and impaired their pro-inflammatory gene transcription.
We next studied whether minocycline also affects early
microglia responses at time points that lack overt cell
death as trigger for migration and reactivity. Furthermore,
we included a vehicle-treated control group in these ex-
periments to exclude potentially protective stress-related
effects. One day after light exposure retinal sections from
control, vehicle- or minocycline-treated mice were stained
with Iba1. Ramified microglia were present in the plexi-
form layers and the ganglion cell layer of control animals
(Fig. 5a). In contrast, retinas from light-exposed and
vehicle-treated mice revealed many amoeboid shaped
microglia in the outer nuclear layer (ONL), which did not
show structural changes at this early time point after light
challenge (Fig. 5b). Minocycline treatment completely
prevented this early microglia migration into the
ONL (Fig. 5c).
We next also analyzed the mRNA expression of
microglia-associated markers in a time kinetic experi-
ment. Light exposure enhanced the expression of the
CD68, AMWAP, and TSPO in vehicle-treated mice
already 1 day after exposure to white light (Fig. 5d–f ).
Minocycline administration dampened the expression of
these genes at every analyzed time point and reached
statistical significance for CD68 (Fig. 5d, vehicle versus
control p < 0.0001, vehicle versus minocycline p = 0.0001
1 day after light exposure) and TSPO (Fig. 5f, vehicle
versus control p = < 0.0001, vehicle versus minocycline
p = 0.0018 1 day after light exposure, and vehicle versus
minocycline p = 0.0113 2 days after light exposure). The
migration marker CCL2 was strongly up-regulated in
light-exposed vehicle controls, reaching statistical signifi-
cance 1 day after light exposure (control versus vehicle
p = 0.0046). Minocycline-treated mice expressed lower
CCL2 at every analyzed time point. Furthermore, mino-
cycline also significantly reduced the expression of IL6,
Fig. 4 Minocycline treatment dampens microglia-related pro-inflammatory marker expression after light exposure. To determine the mRNA expression
of inflammation associated genes in the retina, qRT-PCR analysis were performed 4 days after light exposure. a–c The microglia activation markers CD68
and AMWAP were significantly up-regulated after light exposure, and TSPO levels were also increased. In contrast, retinas from minocycline-treated mice
expressed significantly less CD68 and AMWAP transcripts and also reduced mRNA levels of TSPO. d Minocycline treatment reduced the expression of
CCL2 that was significantly elevated by light exposure. e IL6 was enhanced by light exposure, which was reversed in the minocycline administration
group. f iNOS expression was not significantly altered. Data show mean ± SEM (control n= 4, light exposure n = 4, light exposure and minocycline
treatment n = 5/group, measured in triplicates) with *p < 0.05, **p < 0.01, ***p < 0.001
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which was strongly upregulated in the vehicle-treated
group (Fig. 5h, control versus vehicle p = 0.0082, vehicle
versus minocycline p = 0.0371 1 day after light expos-
ure). In contrast to our previous analysis after 4 days
(Fig. 4f ), iNOS was induced 1 day after light exposure in
vehicle controls and was significantly reduced in the
minocycline administration group (Fig. 5i, control versus
vehicle p < 0.0001, vehicle versus minocycline p = 0.0004
1 day after light exposure).
In a small pilot experiment, we further explored
whether microglia may be even earlier alarmed in the
light damage condition. Indeed, ramified microglia
projected their long protrusions reaching through the
ONL already 4 h after light exposure (Additional file 1:
Figure S1A, B). mRNA analysis in these retinas
clearly showed increased expression of CCL2, IL6,
and CD68 in the absence of changes in caspase 8
levels (Additional file 1: Figure S1C–F). Therefore,
we conclude that microglial activation is an early
event after light exposure that is not only triggered
by dead cells and that minocycline is very effective
in attenuating this process.
Fig. 5 Minocycline suppresses early microglial activation after exposure to bright white light. Representative photomicrographs show retinal
sections (a–c) stained with Iba1 (green) of control, vehicle- or minocycline-treated mice 1 day after light exposure. In healthy controls, microglial
cells are only located in the plexiform layers and GCL (a). Images of light-exposed vehicle-treated mice show amoeboid microglia located in the
ONL, whereas retinal structures appear unaffected 1 day after light exposure (b). Compared to vehicle-treated mice, amoeboid, reactive microglia
are absent in the ONL of mice treated with minocycline (c). ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner
plexiform layer, GCL ganglion cell layer. Scale bar 50 μm. Data show representative photomicrographs (control n = 6, light exposure and vehicle
treatment n = 3, light exposure and minocycline treatment n = 3/group). Retinal mRNA expression of microglia and inflammation-associated genes
were determined by real-time RT-PCR at 1, 2, or 4 days after light exposure (d–i). Compared to controls, the microglial-associated markers CD68,
AMWAP, and TSPO were markedly increased in vehicle-treated mice peaking 1 day after light exposure. Expression levels in minocycline-treated
mice were lower at every analyzed time point (d–f). CCL2 was induced in light-exposed vehicle-treated mice, which was suppressed in the
minocycline-treated group (g). Minocycline treatment also significantly reduced the expression of IL6 and iNOS, which was strongly upregulated in
the vehicle-treated group (h, i). Data show mean ± SEM (control n = 6, light exposure and vehicle treatment n = 3, light exposure and minocycline
treatment n = 3/group, measured in triplicates) with *p < 0.05, **p < 0.01, ***p < 0.001
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Minocycline exerts global anti-inflammatory effects on
the retinal transcriptome
We then asked whether minocycline treatment has a
global effect on gene expression in the light exposure
model of retinal degeneration. RNA-sequencing analysis
with two biological replicates was performed on total
retinal RNA isolated from control mice, from animals
after light exposure, and from light-exposed animals that
received minocycline. We first used the Gene Expression
Dynamics Inspector (GEDI) to determine the global pat-
terns of gene expression in the three different condi-
tions. GEDI is based on self-organizing maps to identify
genome-wide transcriptome activity via “gestalt” recog-
nition [37]. GEDI is sample-oriented rather than gene-
oriented, which allows the identification of genome-wide
patterns. Each mosaic tile in the GEDI map represents a
gene cluster that is expressed at similar levels, with blue
color indicating a low level and red corresponding to
high expression. The three GEDI maps show a highly
dynamic regulation of gene expression in light-exposed
and minocycline-treated retinas compared to control
(Fig. 6a). Light exposure initiated the formation of a
prominent red cluster band that was nearly reversed by
minocycline treatment (Fig. 6a). In the next step, we per-
formed DESeq2 analysis to determine differential gene
expression between the groups using a log2 fold change
cutoff of ≥2. The MA-plots demonstrate that light ex-
posure caused a significant induction of 217 genes with
no down-regulated transcripts (Fig. 6b). In contrast, the
light-exposed versus light-exposed plus minocycline
treatment analysis identified 113 down-regulated and 38
up-regulated transcripts (Fig. 6c). A closer look at the
differentially expressed genes showed that most of the
transcripts induced under light damage conditions be-
long to immune-related biological pathways including
markers directly related to microglia reactivity such as
macrophage scavenger receptor 1 (MSR1), AMWAP
(alias WFDC17), CD68, and complement factor C3
(Additional file 2: Table S1). The vast majority of tran-
scripts down-regulated by minocycline treatment was
induced by light exposure alone, and hence, their ex-
pression was reversed (Additional file 3: Table S2). These
results demonstrate that both light damage and minocy-
cline have a major impact on the global pattern of gene
expression in the retina and that minocycline adminis-
tration effectively counterbalances most of the pro-
inflammatory signaling events in the degenerating retina.
Minocycline treatment protects the retina from
light-induced degeneration
We finally asked whether targeting retinal microglia with
minocycline also improves the outcome of disease pro-
gression. We first performed in vivo optical coherence
tomography (OCT) of mice to detect structural changes
of the retina after light exposure and under conditions of
minocycline treatment. The OCT images showed clear
changes in ONL reflectance in retinas of light-exposed an-
imals, indicating a strong degeneration of the photorecep-
tor layer (Fig. 7a, b). In contrast, minocycline-treated mice
displayed a normal hyperreflective photoreceptor layer
similar to that of controls (Fig. 7c). Volume scans revealed
Fig. 6 Light exposure and minocycline exert global effects on the
retinal transcriptome. a Gene Expression Dynamics Inspector (GEDI)
analysis of the complete RNA-seq dataset (Gene Expression Omnibus
Series Nr. GSE71025) from control retinas and light-exposed retinas
in the absence or presence of minocycline. Biological duplicates
were analyzed for each condition and the pseudo-color scale indi-
cates high (red) or low (blue) expression levels. b, c DESeq2 analysis
to determine differential gene expression between the indicated
groups using a log2 fold change cutoff of ≥2 and ≤−2. The MA-plots
demonstrate that light exposure caused a global induction of 217
genes (b), whereas light exposure plus minocycline administration
reversed this effect with many counter-regulated transcripts (c)
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a severe thinning of the retina, especially in the central
area around the optic nerve head after light exposure,
which was not observed in the minocycline-treated groups
(Fig. 7d–f ). Quantification of the retinal thickness in
all analyzed animals demonstrate a significant reduction
in the central area after light exposure (p < 0.0001),
which could be rescued by treatment with minocycline
(p < 0.0001) (Fig. 7g). To confirm these findings, pano-
rama images of retinal sections proceeding through the
optic nerve head were stained with DAPI. The photo-
receptor layer showed a clear thinning in the group of
mice exposed to light, which was not evident in mice after
minocycline treatment (Fig. 7h–j, Fig. 3a–c). TUNEL
stainings and mRNA analyses of caspase 8 levels also
revealed that light exposure significantly induced cell
death in mouse retinas, which was prevented in
minocycline-treated animals (Fig. 7k–n). These data
clearly point toward a strong neuroprotective effect of
minocycline in conditions of acute light damage.
Discussion
Several studies revealed that minocycline exerts anti-
microbial, anti-inflammatory, anti-apoptotic, and neuro-
protective properties in different animal models of
neuronal degenerative diseases, including Parkinson’s dis-
ease, multiple sclerosis, Alzheimer’s disease, Huntington’s
disease, amyotrophic lateral sclerosis, and retinitis pig-
mentosa [16, 18–20, 23, 25, 42–44]. Here, we report for
Fig. 7 Minocycline prevents light-induced retinal degeneration. a–g SD-OCT was performed 4 days after light exposure to analyze changes in retinal
structures. a–c Light-exposed mice show an altered reflectance in the ONL, which was not present in minocycline-treated mice. d–f Representative
heat maps show the average retinal thickness of control, light-exposed minocycline-treated and untreated mice. Light-exposed mice show a significant
thinning of the retina, especially in the central area, which was preserved by minocycline treatment. g One data point represents the average thickness
of the central retina [μm], calculated from four different areas around the optic nerve head. Data show mean ± SEM (control n = 16 eyes, light exposure
n = 30 eyes, light exposure and minocycline treatment n = 32 eyes). h–j Representative panorama sections of the retina were stained with DAPI to
further characterize structural changes in the retina. Light exposure caused severe degeneration particularly of the ONL. Minocycline administration
reduced degeneration, represented by a clearly thicker photoreceptor layer, scale bar, 200 μM. k–m Representative photomicrographs of
TUNEL-stained retinal sections show the amount of apoptotic cells 4 days after light exposure. Light exposure caused a strong increase of
apoptotic cells, especially in the ONL. Less TUNEL-positive cells were visible after minocycline administration. n RNA analyses revealed a
significantly higher expression of caspase 8 in light-exposed retinas, compared to retinas of minocycline-treated mice, indicating a higher amount of
apoptotic cells. Scale bar, 50 μm. Data show mean ± SEM (control n = 4 retinas, light exposure n = 4 retinas, light exposure and minocycline treatment
n = 5 retinas, measured in triplicates) *p < 0.05, **p < 0.01, ***p < 0.001
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the first time that minocycline administration preserves
the retinal structure in a white light-induced degeneration
model, which mimics several features of dry AMD and
monogenic retinal dystrophies. The main questions
discussed in this study were if and how minocycline
stimulation modulates the neurotoxic potential of micro-
glia and whether minocycline administration could be
a suitable immuno-modulatory strategy to treat retinal
degeneration.
Our in vitro studies in LPS-activated BV-2 microglia
demonstrated that minocycline was capable to diminish
gene expression of the pro-inflammatory markers CCL2,
IL6, and iNOS in a rapid temporal response. This is con-
sistent with earlier reports with microglia isolated from
rat retinas where minocycline dampened mRNA expres-
sion and secretion of IL1β, TNFα, and iNOS [45]. In line
with this, Henry et al. reported that minocycline reduced
mRNA levels of TLR 2, MHC-II, IL1β, and IL6 in BV-2
cells [46]. These results together with our data suggest
that minocycline is highly effective in reducing pro-
inflammatory gene transcription in microglia.
The production of toxic nitric oxide by phagocytes
plays an important role in degenerative processes [47–49].
Here, we demonstrated that minocycline effectively damp-
ened nitric oxide production of LPS-stimulated microglia.
Furthermore, minocycline reduced the general neurotoxic
potential of reactive microglia on 661W photoreceptor
cells. Supernatants from microglia that were stimulated
with both LPS and minocycline were less toxic to photore-
ceptors than those of cells that were treated with LPS
only. Investigations in RAW264.7 macrophages and spinal
cord microglia also confirmed that minocycline blocks the
production of toxic nitric oxide [50, 51]. Hence, others
have found an association of reduced iNOS levels and NO
itself with delayed neurodegeneration [19, 47, 52]. In
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model of Parkinson’s disease, minocycline re-
duced MPP+ induced glial iNOS expression, which
was most likely due to an inhibition of p38 MAPK
phosphorylation [19].
Besides the reduction of NO production, several other
mechanisms of action are discussed for the beneficial ef-
fects of minocycline. Indeed, we here also showed that
minocycline administration directly protected photore-
ceptors from microglia mediated death. In a model of
Huntington’s disease, minocycline delayed disease pro-
gression and mortality by inhibition of caspase-1 and
caspase-3 up-regulation, enzymes which play an import-
ant role in the induction of necrosis and apoptosis [43].
Studies in R6/2 mice confirmed that minocycline can
inhibit both caspase-independent (apoptosis inducing
factor) and caspase-dependent (Smac/Diablo and cyto-
chrome c) mitochondrial cell death pathways [53]. How-
ever, despite its ability to reduce pro-inflammatory markers
in a mouse model for age-related neuron loss, minocycline
failed to inhibit apoptosis and neuron loss [54].
A further mechanism how minocycline exerts its
protective functions is the inhibition of matrix metallo-
proteases (MMPs). MMPs are a family of zinc- and
calcium-dependent proteolytic enzymes that are respon-
sible for the degradation of structural proteins in the
extracellular matrix and their activation is associated
with neurological disorders. Thus, blockage of MMPs by
minocycline decreased the cerebral infarct size in a
mouse model of focal cerebral ischemia. This effect was
most likely due to the inhibition of CCL2, TNFα, and
indoleamine 2,3-dioxygenase (IDO) expression [55, 56].
Our OCT images and immunohistochemical analysis
showed that the treatment with minocycline preserved
retinal structure and reduced the amount of apoptotic
cells after exposure to bright white light. The protection
of photoreceptors was associated with a reduced number
of reactive, amoeboid-shaped, TSPO-positive microglia
in the outer retina. Accordingly, our mRNA analyses of
retinas revealed suppression of microglial activation
markers including AMWAP and CD68 after administra-
tion of minocycline [38–40]. Analysis at different time
points after light exposure revealed that microglial activa-
tion is an early event that precedes photoreceptor death.
Moreover, our RNA-sequencing data revealed a global
transcriptomic effect of minocycline with a complete clus-
ter of light-damage-induced pro-inflammatory genes that
was counter-regulated by minocycline. Of note, the RNA-
seq dataset also detected up-regulation of structural ret-
inal genes such as keratins and adhesion molecules by
minocycline. These results strongly indicate that modula-
tion of microglia reactivity is a key mechanism in minocy-
cline’s mode of action in the retina. This notion is
supported by studies demonstrating that inhibition of
microglia with minocycline protects from neuronal degen-
erative diseases including Alzheimer disease or Parkinson
disease [16, 18]. In the eye, minocycline could also re-
duce microglial activation and improve neuronal func-
tion [13, 25, 57, 58]. In a model of green light
exposure, preservation of retinal structure and ERG
amplitudes by minocycline was associated with re-
duced numbers of CD11b+ cells in the outer retina
[58]. To mimic exposure to bright daylight, which is
discussed as a contributing factor for retinal degener-
ations, we used 15.000 lux UV-free white light in our
studies. White light has an emission spectrum similar
to that of daylight, and it is less artificial than light of a
particular wavelength [59, 60]. Furthermore, white light
contains also short wavelength blue light (403 nm) which
is thought to have a higher damaging potential than light
of longer wavelength including green light (490–580 nm),
which was used in earlier studies [58]. The higher
damaging potential of blue light is due to a process
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called photo-reversal, the regeneration of rhodopsin
from bleaching intermediates that results in a higher
number of photon absorption in a certain time span.
Because of different light exposure settings in our study
and the work of Zhang et al. [58], different underlying
damage mechanisms cannot be ruled out [28, 59, 61, 62].
In the rd10 mouse model for retinitis pigmentosa,
minocycline inhibited microglial activation and down-
regulated the expression of pro-inflammatory molecules
including TNFα, COX1, and COX2. Moreover, pro-
apoptotic molecules such as BAX and Caspase 3 were
suppressed by minocycline, and the retinal structure and
function were preserved [25]. Of note, minocycline could
also diminish photoreceptor death in rds mice by a
microglia-independent mechanism as depletion of micro-
glia by clodronate prevented their recruitment but failed
to inhibit photoreceptor apoptosis [63].
Conclusions
We have shown that microglia activity is an early event in
retinal degeneration induced by bright white light. Mino-
cycline administration preserved the retinal structure by a
global counter-regulation of microglial pro-inflammatory
responses and direct effects on photoreceptors during
light exposure. Our data suggest that treatment strategies
that modulate microglial reactivity and support photo-
receptor survival provide a potential therapeutic option
for retinal degenerative diseases.
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